Brief: ArgenX Advances Clinical Development Of ARGX-119
30/06/2025 06:40
June 30 (Reuters) - argenx SE ARGX.BR: ADVANCES CLINICAL DEVELOPMENT OF ARGX-119 IN CONGENITAL MYASTHENIC SYNDROMES ADVANCE TO REGISTRATIONAL STUDY IN PATIENTS WITH CONGENITAL MYASTHENIC SYNDROMES (CMS) Source text: ID:nNDL990jfT Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles